Journal Home > Volume 9 , Issue 2
Objective:

To evaluate the long-term curative efficacy and safety of olfactory ensheathing cell (OEC) transplantation by 10 years of follow-up investigation.

Methods:

A follow-up observation was done on 13 patients with allograft olfactory bulb-derived OEC transplantation from September 2005 to September 2007 at the Second Affiliated Hospital of Xi’an Jiaotong University. After cell purification, amplification, and identification, a 2 × 107/mL cell suspension was prepared for transplantation. In the posterior horn of the spinal cord 0.5 cm distal and proximal to the spinal cord injury zone, 4 needle points were selected to avoid the blood vessels. The needle depth was 3 mm, and the injection volume per point was 10 μL. Postoperatively and at 1 week, 4 weeks, 12 weeks, 24 weeks, 1 year, 3 years, 5 years, and 10 years after the surgery, the patient’s American Spinal Injury Association (ASIA) score, adverse reactions, and other minor observations were assessed.

Results:

All the patients did not have serious complications. No gliomas or other new organisms formed during the 10-year observation period. Eight of 13 patients had improvement in sensory function, and 5 patients showed improvement in motor function. The ASIA acupuncture, light touch, and exercise scores improved significantly 1 year after the surgery, and this improvement continued until the 10-year follow-up period. Three of 13 patients had improvement in defecation and urination, and 1 patient had improved neuralgia after spinal cord injury.

Conclusion:

OEC transplantation is safe and effective in treating spinal cord injury. The observation period of OEC transplantation is 1 to 3 years.


menu
Abstract
Full text
Outline
About this article

Ten years of clinical observation of olfactory ensheathing cell transplantation in patients with spinal cord injury

Show Author's information Zhijian Cheng1,§Rui Wang1,2,§Kai Cao1Guoyu Wang1Jie Qin1Haopeng Li1Jiaxi Li1Dong Wang1( )Xijing He1,3( )
Second Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi, China
Department of Orthopaedics, Postdoctoral Research Center, Xi’an Gaoxin Hospital, Xi'an 710075, Shaanxi, China
Xi’an International Medical Center Hospital, Xi’an 710100, Shaanxi, China

§ These authors contributed equally to this work.

Abstract

Objective:

To evaluate the long-term curative efficacy and safety of olfactory ensheathing cell (OEC) transplantation by 10 years of follow-up investigation.

Methods:

A follow-up observation was done on 13 patients with allograft olfactory bulb-derived OEC transplantation from September 2005 to September 2007 at the Second Affiliated Hospital of Xi’an Jiaotong University. After cell purification, amplification, and identification, a 2 × 107/mL cell suspension was prepared for transplantation. In the posterior horn of the spinal cord 0.5 cm distal and proximal to the spinal cord injury zone, 4 needle points were selected to avoid the blood vessels. The needle depth was 3 mm, and the injection volume per point was 10 μL. Postoperatively and at 1 week, 4 weeks, 12 weeks, 24 weeks, 1 year, 3 years, 5 years, and 10 years after the surgery, the patient’s American Spinal Injury Association (ASIA) score, adverse reactions, and other minor observations were assessed.

Results:

All the patients did not have serious complications. No gliomas or other new organisms formed during the 10-year observation period. Eight of 13 patients had improvement in sensory function, and 5 patients showed improvement in motor function. The ASIA acupuncture, light touch, and exercise scores improved significantly 1 year after the surgery, and this improvement continued until the 10-year follow-up period. Three of 13 patients had improvement in defecation and urination, and 1 patient had improved neuralgia after spinal cord injury.

Conclusion:

OEC transplantation is safe and effective in treating spinal cord injury. The observation period of OEC transplantation is 1 to 3 years.

Keywords: olfactory ensheathing cells, cell transplantation, spinal cord injury, clinical observation, retrospective analysis

References(10)

[1]
Li Y, Field PM, Raisman G. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 1997, 277(5334): 2000-2002.
[2]
Watzlawick R, Rind J, Sena ES, et al. Olfactory ensheathing cell transplantation in experimental spinal cord injury: effect size and reporting bias of 62 experimental treatments: a systematic review and meta-analysis. PLoS Biol 2016, 14(5): e1002468.
[3]
Li L, Adnan H, Xu B, et al. Effects of transplantation of olfactory ensheathing cells in chronic spinal cord injury: a systematic review and meta-analysis. Eur Spine J 2015, 24(5): 919-930.
[4]
Lima C, Pratas-Vital J, Escada P, et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 2006, 29(3): 191-203; discussion 204.
[5]
Huang H, Xi H, Chen L, et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant 2012, 21(Suppl 1): S23-S31.
[6]
Moviglia GA, Fernandez Viña R, Brizuela JA, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006, 8(3): 202-209.
[7]
Beijing declaration of international association of neurorestoratology (IANR). Cell Transplant 2009, 18(4): 487.
[8]
Pascual JI, Gudiño-Cabrera G, Insausti R, et al. Spinal implants of olfactory ensheathing cells promote axon regeneration and bladder activity after bilateral lumbosacral dorsal rhizotomy in the adult rat. J Urol 2002, 167(3): 1522-1526.
[9]
Lang BC, Zhang Z, Lv LY, et al. OECs transplantation results in neuropathic pain associated with BDNF regulating ERK activity in rats following cord hemisection. BMC Neurosci 2013, 14: 80.
[10]
Luo Y, Zou Y, Yang LH, et al. Transplantation of NSCs with OECs alleviates neuropathic pain associated with NGF downregulation in rats following spinal cord injury. Neurosci Lett 2013, 549: 103-108.
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 09 May 2021
Revised: 30 May 2021
Accepted: 22 June 2021
Published: 05 June 2021
Issue date: June 2021

Copyright

© The authors 2021

Acknowledgements

We would like to acknowledge all the patients and families who participated in this trial.

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return